首页 > 用药指导 > 文章详情

Baricitinib(艾乐明)巴瑞替尼的作用与副作用

发布时间:2024-01-18 15:08:01 阅读:1060 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

巴瑞替尼片

巴瑞替尼片 生产厂家:孟加拉DIL耀品国际制药公司 功能主治:对一种或多种抗风湿药物缓解不足或不耐受的中度至重 用法用量:用法用量  1、类风湿性关节炎  OLUMIANT的推荐剂量为每日1次口服2mg,餐前餐后都可。  OLUMIANT可以单独使用,也可以与甲氨蝶呤或其他非生物dmard联合使用。  2、COVID-19(新冠病毒)  成人OLUMIANT的推荐剂量为每日一次口服4mg,餐前餐后都可,持续14天或直到出院,以先发生者为准。  3、斑秃  OLUMIANT的推荐剂量是2mg,每天一次口服,餐前餐后都可。  如果对治疗的反应不充分,增加到每天一次4mg。  对于几乎完全或完全的头皮脱发,睫毛或眉毛有或没有大量脱发的患者,考虑每天一次4mg治疗,伴餐前餐后都可。  一旦患者对4mg的治疗产生了充分的反应,将剂量减少到2mg,每天一次。  对于无法吞下整片药片的患者,可以考虑另一种给药方式:  1、口服分散  2、胃造口管(G管)  3、鼻胃管(NG管)或口胃管(OG管)
查看详情

Baricitinib(艾乐明)巴瑞替尼的作用与副作用,Baricitinib(Baricitinib)常见副作用有:1、严重感染,如肺炎、带状疱疹和尿路感染;2、死亡率,50岁以上及有心血管疾病的患者有更高的全因死亡率;3、恶性肿瘤和淋巴增生性疾病;4、重大心血管不良事件;5、血栓形成;6、会出现过敏反应;7、胃肠道穿孔;8、可能会对胎儿造成损害。

Baricitinib (trade name Olumiant) is a medication that has shown effectiveness in the treatment of various conditions such as rheumatoid arthritis, COVID-19, and alopecia areata. While it can provide relief to patients, it is important to be aware of both its benefits and potential side effects. In this article, we will explore the uses and side effects of Baricitinib.

1. Baricitinib and Rheumatoid Arthritis:

Baricitinib is primarily used for the treatment of rheumatoid arthritis (RA), a chronic inflammatory autoimmune disease that primarily affects the joints. It belongs to a class of drugs called Janus kinase (JAK) inhibitors, which work by inhibiting specific enzymes involved in the body's immune response. By reducing inflammation, Baricitinib can help alleviate the symptoms of RA, including joint pain, stiffness, and swelling. It is typically prescribed to patients who have not responded well to other disease-modifying antirheumatic drugs (DMARDs).

2. Baricitinib and COVID-19:

During the COVID-19 pandemic, Baricitinib gained attention for its potential role in the treatment of the disease caused by the SARS-CoV-2 virus. Studies have shown that Baricitinib can help modulate the immune response and reduce inflammation associated with severe COVID-19. When used in combination with other medications such as remdesivir, Baricitinib has demonstrated the ability to improve clinical outcomes in hospitalized COVID-19 patients, particularly those who require supplemental oxygen or ventilator support.

3. Baricitinib and Alopecia Areata:

Alopecia areata is an autoimmune condition that causes sudden hair loss, usually in round or oval patches on the scalp or other areas of the body. Baricitinib has shown promise in the treatment of moderate to severe alopecia areata by suppressing the immune response targeting hair follicles. By inhibiting specific JAK enzymes, Baricitinib can interrupt the signaling pathways involved in the autoimmune attack on hair follicles. However, more research is needed to determine the full effectiveness and optimal dosage of Baricitinib for this condition.

4. Side Effects of Baricitinib:

While Baricitinib can provide significant therapeutic benefits, it is important to be aware of its potential side effects. Common side effects include upper respiratory tract infections, headache, nausea, and an increase in cholesterol levels. More serious side effects can occur, such as infections, liver enzyme elevations, blood clots, and an increased risk of malignancies. Patients taking Baricitinib should be closely monitored by their healthcare provider and promptly report any unusual symptoms or side effects.

In conclusion, Baricitinib (Olumiant) is a medication with diverse applications, including the treatment of rheumatoid arthritis, COVID-19, and alopecia areata. While it can offer significant relief to patients, it is crucial to balance the potential benefits with an understanding of the associated side effects. Patients considering or currently taking Baricitinib should consult with their healthcare provider to determine the appropriate treatment plan and to address any concerns or questions they may have.